Sawai Announces Listing of Five Generic Drugs with Nine Strengths

Dec. 09. 2021

Osaka, Japan - December 9, 2021 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the listing of five generic drugs with nine strengths in the NHI (National Health Insurance) drug price list. Sawai’s product line now includes 331 compounds with 817 strengths.

The list of approved products

1. Levetiracetam Tablets, Granular Tablets, DS

Generic name Levetiracetam
Strengths Tablets, Granular Tablets: 250 mg, 500 mg, DS: 50%
Brand products E Keppra® Tablets 250 mg, 500 mg, E Keppra® Dry syrup 50%

2. Ambrisentan Tablets

Generic name Ambrisentan
Strengths Tablets: 2.5 mg
Brand products Volibris Tablets 2.5 mg

3. Olopatadine Ophthalmic Solution

Generic name Olopatadine
Strengths Ophthalmic Solution: 0.1%
Brand products Patanol® Ophthalmic Solution 0.1%

4. Iguratimod Tablets

Generic name Iguratimod
Strengths Tablets: 25 mg
Brand products Careram® Tablets 25 mg

5. Bortezomib Injection

Generic name Bortezomib
Strengths Injection: 3 mg
Brand products VELCADE® Injection 3 mg

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.